This activity is jointly provided by Global Education Group and Integritas Communications.
This activity is supported by an educational grant from Genzyme, a Sanofi Company, and Regeneron Pharmaceuticals.
Atopic dermatitis is a chronic inflammatory condition with manifestations in the skin and other organ systems throughout the body.1 Increasing in prevalence over the last 2 decades, the disease places tremendous burdens on adult, adolescent, and pediatric patients, as well as family members and caregivers.1,2 A better understanding of disease pathophysiology and effects on patient health and quality of life highlight the need for prompt diagnosis and proactive management.3,4 Moreover, research into the mechanisms underlying atopic dermatitis pathogenesis and progression supports the development of new approaches to disease characterization, ongoing patient monitoring, and treatment.5,6 During this Evidence-Based Best Practices program, expert faculty will discuss clinically relevant disease pathophysiology; comprehensive patient evaluations; the efficacy and safety of current therapies for moderate-to-severe disease; and the latest evidence for emerging biologic agents. With the overall goal of improving outcomes for patients with active atopic dermatitis, the program will integrate clinical data and professional experience into actionable recommendations that can be used to individualize care and improve patient-clinician communication. __________________________________
References: 1. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015:66(suppl 1):8-16. 2. Drucker AM, et al. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137(1):26-30. 3. Eichenfield LF, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338-351. 4. Sidbury R, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2): 327-349. 5. Ungar B, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol. 2016 Nov 4. [Epub ahead of print]. 6. Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016 Sep 30. [Epub ahead of print].
The educational design of this activity addresses the needs of dermatologists and other healthcare professionals involved in the treatment of patients with atopic dermatitis.
Upon completion of this activity, participants will be better prepared to:
Discuss atopic dermatitis pathophysiology, focusing on clinically relevant disease mechanisms, risk factors, and novel therapeutic targets
Comprehensively assess patients with atopic dermatitis to determine symptom severity, characterize potential phenotypes, identify comorbidities, and document treatment responses
Describe the clinical profiles of current and emerging biologic therapies for moderate-to-severe atopic dermatitis
Individualize therapy for moderate-to-severe atopic dermatitis to prevent outbreaks, maximize health-related quality of life, manage comorbidities, and minimize treatment-related adverse effects
Communicate with patients and, when necessary, caregivers to improve their understanding of atopic dermatitis and secondary complications, while facilitating shared decision-making
Conflict Of Interest Disclosure Policy
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
Jeffrey M. Weinberg, MD Associate Clinical Professor of Dermatology Mount Sinai School of Medicine New York, NY Director, Division of Dermatology Jamaica Hospital Medical Center Richmond Hill, NY
Dr. Weinberg discloses the following: Grant/Research Support: Regeneron Pharmaceuticals, Inc.
Lawrence F. Eichenfield, MD Professor of Dermatology and Pediatrics Vice Chair, Department of Dermatology University of California, San Diego, School of Medicine Chief, Pediatric and Adolescent Dermatology Rady Children’s Hospital and Health Center San Diego, CA
Dr. Eichenfield discloses the following: Consultant/Independent Contractor: Anacor Pharmaceuticals, Inc.; Eli Lilly and Company; Genentech, Inc.; Medimetriks Pharmaceuticals, Inc.; Otsuka America Pharmaceutical, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC.; Top MD, Inc.; Valeant Pharmaceuticals International, Inc. Grant/Research Support: Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC.
Howard Sofen, MD Associate Clinical Professor of Medicine/Dermatology and Pediatrics University of California, Los Angeles (UCLA) David Geffen School of Medicine Chief of Dermatology Los Angeles County/Olive View-UCLA Medical Center Los Angeles, CA
Dr. Sofen discloses the following: Consultant/Independent Contractor: Celgene Corporation; Regeneron Pharmaceuticals, Inc.; Roche Laboratories, Inc. Grant/Research Support: AbbVie Inc.; AstraZeneca; Celgene Corporation; DermAvance Pharmaceuticals, Inc.; Glenmark Pharmaceuticals Inc.; Incyte Corporation; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; Roche Laboratories, Inc. Honoraria: Regeneron Pharmaceuticals, Inc. Speakers Bureau: Genentech, Inc.; Novartis Pharmaceuticals Corporation
Planners' and Managers' Disclosures
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:
Lindsay Scott has nothing to disclose. Andrea Funk has nothing to disclose. Laura Gilsdorf has nothing to disclose. Jim Kappler, PhD, has nothing to disclose. Rose O’Connor, PhD, has nothing to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas. Global is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Integritas Communications do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Fee and Refund / Cancellation Policy
There is no fee for this educational activity.
In order to receive credit, participants must complete the pre-assessment questions, post-test, and program evaluation. Participants must also score at least 70% on the post-test. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.